

Fact Sheet for Healthcare Providers: Interpreting Results from the Aptima® Zika Virus Assay

Updated: March 8, 2018

Dear Healthcare Provider:

The US Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to authorize the use of the Aptima® Zika Virus assay for the *in vitro* qualitative detection of Zika virus with specified instruments. This assay tests for Zika virus RNA in human in serum, plasma, processed urine or processed whole blood K2EDTA (whole blood and urine collected alongside a patient-matched serum or plasma specimen). Testing should be conducted on specimens from people who meet Centers for Disease Control and Prevention (CDC) Zika clinical and/or epidemiological criteria for testing and be performed laboratories in the United States (US) that are certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity tests, or by similarly qualified non-US laboratories (see www.cdc.gov/zika/hc-providers/index.html). This test is should be performed according to CDC's algorithm for Zika testing (see <http://www.cdc.gov/zika/laboratories/lab-guidance.html>).

The information in this Fact Sheet is to inform you of the significant known and potential risks and benefits of the emergency use of the Aptima Zika Virus assay (see www.fda.gov/MedicalDevices/Safety/EmergencySituations/ucm161496.htm).

Why is this test needed at this time?

Public health officials have determined that Zika virus poses a potential public health emergency. Current information on Zika virus infection for healthcare providers, including case definitions and information about signs and symptoms, is available at www.cdc.gov/zika/hc-providers/index.html. All information and guidance, including those on Zika virus laboratory testing, may change as more data are gathered on this virus. Please check CDC's Zika virus website regularly for the most current information (www.cdc.gov/zika/index.html).

The US Secretary of Health and Human Services (HHS) has declared that circumstances exist to justify the emergency use of *in vitro* diagnostic tests for the detection of Zika virus and/or diagnosis of Zika virus infection. This EUA will terminate when the HHS Secretary's declaration terminates, unless FDA revokes it sooner.

At this time, there are no FDA approved/cleared tests available that can detect Zika virus in clinical specimens in the United States. Therefore, Hologic, Inc. has developed the Aptima Zika Virus assay to detect evidence of Zika virus infection.

When should the Aptima Zika Virus assay be performed?

If Zika virus infection is suspected based on CDC's published clinical and/or epidemiological criteria, the Aptima Zika Virus assay may be ordered and should be performed according to the CDC-issued guidance (<http://www.cdc.gov/zika/laboratories/lab-guidance.html>). The algorithms included within the guidance illustrate the appropriate Zika testing approach based on the presence of signs and symptoms, pregnancy status, and the time between onset of

symptoms or suspected exposure and specimen collection.

As disease manifestations of dengue and chikungunya virus infections can resemble those of Zika virus infection, additional testing for these viruses should be considered to aid in differentiating dengue and chikungunya virus infections from Zika virus infections or identifying possible co-infections. Please contact your state or local health department to facilitate testing.

Zika virus RNA is typically detectable in serum during the acute phase of infection (generally up to 7 days post-symptom onset). Zika virus RNA has been detected in serum up to 13 days post-symptom onset in non-pregnant patients, and up to 62 days post-symptom onset in pregnant patients. In addition, Zika virus RNA has been detected up to 53 days after the last known possible exposure in an asymptomatic pregnant woman (references 3-4).

As of March 8, 2018, serum is the primary diagnostic specimen for Zika virus RNA and serologic testing, and should be the priority specimen for collection and Aptima Zika Virus assay testing. The Aptima Zika Virus assay can also be used to test plasma, processed urine or processed whole blood K2EDTA (whole blood and urine collected alongside a patient-matched serum or plasma specimen). While some data suggest that Zika virus RNA may be detectable for longer periods of time in other bodily fluids, such as whole blood and urine, when compared to serum, persistence of Zika virus RNA in these other bodily fluids is not well characterized.

Along with serum specimens, healthcare providers are strongly encouraged to collect and submit additional recommended specimens (per CDC guidance), such as urine and whole blood, to provide additional opportunities for detection of Zika virus infection. However, a patient-matched serum specimen should always be submitted with a urine specimen to facilitate reflex testing as outlined in the current CDC-issues algorithm (<http://www.cdc.gov/zika/laboratories/lab-guidance.html>).

Specimens should be collected with appropriate infection control precautions and according to the manufacturer's instructions for the specimen collection device, handling, and storage. Serum should be collected in serum separator tubes and centrifuged after collection to reduce the likelihood of hemolysis. Whole blood specimens should be collected in K2EDTA tubes for use with the Aptima Zika Virus assay testing. Additional guidance for collection of body fluid specimens for Zika diagnostic testing may be found at: <http://www.cdc.gov/zika/laboratories/test-specimens-bodyfluids.html>.

If your patient has been symptomatic but is beyond the recommended window for Aptima Zika Virus assay testing, serologic testing for antibodies to Zika virus may be helpful.

What does it mean if the specimen tests positive for Zika virus RNA?

A positive test result for Zika virus from the Aptima Zika Virus assay indicates that RNA from Zika virus was detected in the patient's specimen. A positive test result in any specimen collected from a patient is indicative of Zika virus infection. Laboratory test results should always be considered in the context of clinical observations, epidemiological data, and travel history in making a final diagnosis and patient management decisions. For guidance on Zika virus, please refer to www.cdc.gov/zika/hc-providers/index.html.

The Aptima Zika Virus assay has been designed to minimize the likelihood of false positive test results. Cross-reactivity of any of the components of this test resulting in false positive results is not expected. However, in the event of a false positive result, risks to patients could include any or

Hologic, Inc.

Aptima® Zika Virus Assay

all of the following: impaired ability to detect and receive appropriate medical care for the true source of symptoms; in the case of pregnant women, an unnecessary increase in the monitoring of a woman's pregnancy; other unintended adverse effects.

In the US and its territories, Zika virus infection and disease (non-congenital and congenital) are nationally notifiable conditions and should be reported to the local or state health department. For guidance on Zika virus, please refer to <http://www.cdc.gov/zika/hc-providers/index.html>.

While there is an established association between Zika virus infection during pregnancy and microcephaly, detection of Zika virus RNA in specimens collected from a pregnant woman does not provide definitive information about the health of her fetus and does not indicate imminent harm to her fetus. If a pregnant woman is diagnosed with Zika virus infection based on detection of Zika virus RNA, issues such as timing of infection during the course of pregnancy, presence of symptoms and other factors may help determine the risk to her fetus.

What does it mean if the specimen tests negative for Zika virus RNA?

A negative test result for Zika virus in the specimen means that RNA from Zika virus is not present in the specimen above the test's limit of detection. However, a negative result does not rule out infection with the virus and should not be used as the sole basis for treatment or other patient management decisions.

It is especially important to note that negative results in urine or whole blood, which are not the recommended primary diagnostic specimen types, do not necessarily mean that a person is not infected. When results are negative for urine or whole blood, the patient-matched serum or plasma specimen should be tested as outlined in the current CDC-issued algorithm (<http://www.cdc.gov/zika/laboratories/lab-guidance.html>).

A negative Aptima Zika Virus assay result does not exclude the possibility of Zika virus infection. In serum, negative rRT-PCR test results are known to occur in Zika virus infection, particularly if testing is conducted outside the acute phase of infection (generally up to 7 days post symptom-onset) or in asymptomatic people. When other diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with Zika virus infection. Such patients should have antibody testing performed on their serum sample, as per the CDC testing algorithm (found at <http://www.cdc.gov/zika/laboratories/lab-guidance.html>).

Absence of laboratory evidence of Zika virus infection cannot definitively rule out Zika virus infection in persons with epidemiological risk factors. All results should be considered in the context of clinical signs and symptoms, exposure risk and time since symptom onset, or in the absence of symptoms, time since exposure.

Guidance for healthcare providers, including those caring for pregnant women and women of reproductive age with possible Zika virus exposure, is available on the CDC website: www.cdc.gov/zika/hc-providers/index.html.

Reporting Adverse Events

You should report adverse events, including problems with test performance or results, to MedWatch at <http://www.fda.gov/Safety/MedWatch/default.htm>, by completing and submitting the online FDA Form 3500 for Health Professionals (available at

Hologic, Inc.

Aptima® Zika Virus Assay

<https://www.accessdata.fda.gov/scripts/medwatch/index.cfm?action=reporting.home>) or by calling 1-800-FDA-1088.

All patients should receive the Fact Sheet for Patients: Understanding Results from the Aptima Zika Virus assay

Contact Information for the Manufacturer:

Hologic, Inc.

10210 Genetic Center Drive

San Diego, CA 92121

Phone: +1- 800-442-9892

E-mail: customersupport@hologic.com

Any significant new findings that negatively impact the performance of the test and that are observed during the course of the emergency use of the Aptima Zika Virus assay will be made available at <http://www.hologic.com/>.

References

- 1) Rasmussen, S.A., Jamieson, D.J., Honein, M.A., Petersen, L.R. Zika Virus and Birth Defects – Reviewing the Evidence for Causality. *New England Journal of Medicine*, May 19, 2016; 374:1981-1987. DOI: 10.1056/NEJMSr1604338.
- 2) CDC Website - <http://www.cdc.gov/zika/>
- 3) Driggers, R.W., et al. Zika virus Infection with Prolonged Maternal Viremia and Fetal Brain Abnormalities. *New England Journal of Medicine*, June 2, 2016; 374:2142-2151. DOI: 10.1056/NEJMoa1601824
- 4) Meaney-Delman et al. Prolonged Detection of Zika Virus RNA in Pregnant Women. *Obstetrics and Gynecology*, October, 2016; 128: 724-730. DOI:[10.1097/AOG.0000000000001625](https://doi.org/10.1097/AOG.0000000000001625)